skip to main content
Primo Search
Search in: Busca Geral

Co-mutations in tumor immune microenvironment and immunotherapy

Ma, Ling ; Zhu, Ling-Jun ; Xu, Zi-Jie ; Shu, Yong-Qian

Chinese medical journal, 2021-05, Vol.134 (9), p.1055-1057 [Periódico revisado por pares]

China: Lippincott Williams & Wilkins Ovid Technologies

Texto completo disponível

Citações Citado por
  • Título:
    Co-mutations in tumor immune microenvironment and immunotherapy
  • Autor: Ma, Ling ; Zhu, Ling-Jun ; Xu, Zi-Jie ; Shu, Yong-Qian
  • Assuntos: Biomarkers ; Cancer therapies ; Chemotherapy ; Cyclin-dependent kinases ; Cytokines ; Genes ; Genomes ; Immune system ; Immunotherapy ; Kinases ; Lung cancer ; Lymphocytes ; Medical Progress ; Metastasis ; Mutation ; Proteins ; Tumors
  • É parte de: Chinese medical journal, 2021-05, Vol.134 (9), p.1055-1057
  • Descrição: [...]the response rates to the ICIs in cancer patients are relatively low and the results of the reported biomarkers for predicting the treatment efficacy are conflicting. [...]novel and reliable biomarkers are urgently needed to monitor tumor-specific immune responses, avoid immune-related adverse events, and improve clinical efficacy. [...]the data about the efficacy of ICIs or ICIs combined with chemotherapy in patients with KP co-mutations compared with those with KRAS single mutation are rarely reported. [...]more clinical studies especially the multi-center prospective randomized controlled trials are taken into consideration. Kron et al[10] reported that PD-L1 positivity is significantly associated with TP53 mutation status in 34 ALK-positive patients. [...]ALK and TP53 co-mutations likely have a positive influence on the clinical efficacy of ICIs. [...]a large number of NSCLC patients with ALK and TP53 co-mutations are needed to analyze the association of co-mutations with TIME and immunotherapy.
  • Editor: China: Lippincott Williams & Wilkins Ovid Technologies
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.